World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
47
Citations
9832
World Ranking
4498
National Ranking
2034

David H. McDermott publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David H. McDermott sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 104 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David H. McDermott D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David H. McDermott sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 47 D-Index — 9th percentile

9% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

David H. McDermott is affiliated with the National Institutes of Health in the United States. Their research spans multiple areas within medicine, particularly focusing on immunology and oncology. The bulk of their academic contributions address topics such as cancer immunotherapy and biomarkers, renal cell carcinoma treatment, and immunodeficiency and autoimmune disorders.

The scientist has produced significant work related to chemokine receptors and signaling, immunotherapy and immune responses, immune cell function and interaction, and T-cell and B-cell immunology. These thematic areas illustrate a strong focus on understanding immune mechanisms and their applications to disease treatment, especially in cancer and immune-related conditions.

David H. McDermott has collaborated frequently with several researchers in their field. These frequent co-authors include:

  • Philip M. Murphy
  • Shamik Majumdar
  • Toni K. Choueiri
  • Karl Balabanian
  • Amélie Bonaud

Their research has been published in various scientific journals, with multiple publications appearing in the following venues:

  • Journal of Clinical Oncology
  • Blood
  • Journal of Allergy and Clinical Immunology
  • Journal of Clinical Immunology
  • The Journal of Immunology

Selected recent papers authored or co-authored by David H. McDermott include:

  • Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study, 2024, The Lancet Oncology
  • Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity, 2021, Journal of Allergy and Clinical Immunology
  • Discovery of several thousand highly diverse circular DNA viruses, 2020, eLife
  • Absence of mucosal-associated invariant T cells in a person with a homozygous point mutation in MR1, 2020, Science Immunology
  • Clinical exome sequencing of 1000 families with complex immune phenotypes: Toward comprehensive genomic evaluations, 2022, Journal of Allergy and Clinical Immunology

Their scholarly output covers major fields of study including medicine and immunology and microbiology. Among subfields, the scientist's work spans immunology, oncology, pulmonary and respiratory medicine, molecular biology, and hematology.

Best Publications

  • CCR5 deficiency increases risk of symptomatic West Nile virus infection.

    William G. Glass;David H. McDermott;Jean K. Lim;Sudkamon Lekhong

  • CCR5 promoter polymorphism and HIV-1 disease progression

    David H McDermott;Peter A Zimmerman;Peter A Zimmerman;Florence Guignard;Cynthia A Kleeberger

  • Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor.

    Ji-Liang Gao;D. B. Kuhns;H. L. Tiffany;D. Mcdermott

  • Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease

    Didier Moatti;Sophie Faure;Frédéric Fumeron;Mohamed El Walid Amara

  • Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.

    Sophie Faure;Laurence Meyer;Dominique Costagliola;Céline Vaneensberghe

  • Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans.

    David H. McDermott;Alan M. Fong;Qiong Yang;Joan M. Sechler

  • CCL2 Polymorphisms Are Associated With Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study

    David H. McDermott;Qiong Yang;Sekar Kathiresan;L. Adrienne Cupples

  • Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis

    David H. McDermott;Julian P.J. Halcox;William H. Schenke;Myron A. Waclawiw

  • A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family.

    P M Murphy;T Ozçelik;R T Kenney;H L Tiffany

  • Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man

    Jean K. Lim;Andrea Lisco;David H. McDermott;Linda Huynh

  • Human T and Natural Killer Cells Possess a Functional Renin-Angiotensin System: Further Mechanisms of Angiotensin II–Induced Inflammation

    Mollie Jurewicz;David H. McDermott;Joan M. Sechler;Kathryn Tinckam

  • Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort study

    David H. McDermott;Matthew J. Beecroft;Cynthia A. Kleeberger;Fadwa M. Al-Sharif

  • Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta-Analysis of 4 Cohorts in the US Epidemic

    Jean K. Lim;Christine Y. Louie;Carol Glaser;Cynthia Jean

  • Chromothriptic Cure of WHIM Syndrome

    David H. McDermott;Ji-Liang Gao;Qian Liu;Marie Siwicki

  • Chemokine Receptor Polymorphism and Risk of Acute Rejection in Human Renal Transplantation

    Reza Abdi;Tran Thi Bich Huong;Alfredo Sahagun-Ruiz;Philip M. Murphy

  • Discovery of several thousand highly diverse circular DNA viruses.

    Michael J. Tisza;Diana V. Pastrana;Nicole L. Welch;Brittany Stewart

  • A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

    David H. McDermott;Qian Liu;Daniel Velez;Lizbeeth Lopez

  • Complete Genome Sequence of a Tenth Human Polyomavirus

    Christopher B. Buck;Giao Q. Phan;Manish T. Raiji;Philip M. Murphy

  • Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C

    Kittichai Promrat;David H. McDermott;Carlos M. Gonzalez;David E. Kleiner

  • The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

    David H. McDermott;Qian Liu;Jean Ulrick;Nana Kwatemaa

Frequent Co-Authors

Philip M. Murphy
Philip M. Murphy National Institutes of Health
Ji-Liang Gao
Ji-Liang Gao National Institute of Allergy and Infectious Diseases
Harry L. Malech
Harry L. Malech National Institutes of Health
Douglas B. Kuhns
Douglas B. Kuhns National Institutes of Health
Jean K. Lim
Jean K. Lim Icahn School of Medicine at Mount Sinai
Christopher B. Buck
Christopher B. Buck National Institutes of Health
Arvind Varsani
Arvind Varsani Arizona State University
Christophe Combadière
Christophe Combadière Sorbonne University
Stefania Pittaluga
Stefania Pittaluga National Institutes of Health
Alison A. McBride
Alison A. McBride National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology in the USA opens doors to a variety of healthcare and scientific careers. Many students interested in clinical roles often complement their immunology knowledge with nursing degrees. For those looking to advance quickly, accelerated NP programs online offer a streamlined path to becoming a Nurse Practitioner. These programs are designed for efficiency without compromising on quality.

For individuals without a nursing background, online ABSN programs for non nurses provide an excellent opportunity to enter the nursing field and apply immunology concepts in patient care. These accelerated pathways help non-nurses transition smoothly into healthcare professions.

If you’re looking for options that are easier to gain admission to, exploring accelerated nursing programs near me can be a practical first step. Such programs allow students to build a solid foundation in nursing while integrating their immunology expertise.

Additionally, starting with foundational roles through easy LPN programs to get into can provide valuable hands-on experience. These practical nursing roles complement immunology knowledge and open pathways to further specializations.

Best Scientists Citing David H. McDermott

Trending Scientists

Recently Published Articles